Adjunct diagnostic value of radiological findings in mucopolysaccharidosis type IVa-related thoracic spinal abnormalities: a pilot study

Ya‑Ting Jan1,3,4,5, Pei‑Shan Tsai1,3,4,5, Wen‑Hui Huang1,3,4,5, Shih‑Chieh Huang1,4,5, Yu‑Peng Liu2, She‑Meng Cheng1,4,5 and Kun‑Shuo Huang1,4,5*

Abstract

Background: In patients with mucopolysaccharidosis (MPS), systematic assessment and management of cervical instability, cervicomedullary and thoracolumbar junction spinal stenosis and spinal cord compression averts or arrests irreversible neurological damage, improving outcomes. However, few studies have assessed thoracic spinal involvement in MPS IVa patients. We aimed to evaluate thoracic spinal abnormalities in MPS IVa patients and identify associated image manifestations by CT and MRI study.

Results: Data of patients diagnosed and/or treated for MPS IVa at MacKay Memorial Hospital from January 2010 to December 2020 were extracted from medical records and evaluated retrospectively. Computed tomography (CT), plain radiography and magnetic resonance imaging (MRI) findings of MPS IVa-related spinal abnormalities were reviewed. Spine CT and plain radiography findings of 12 patients (6 males and 6 females with median age 7.5 years, range 1–28 years) revealed two subtypes of spinal abnormalities: thoracic kyphosis apex around T2 (subtype 1, n = 8) and thoracic kyphosis apex around T5 (subtype 2, n = 4). Spine CT and plain radiography clearly identified various degrees of thoracic kyphosis with apex around T2 or T5 in MPS IVa patients. Square‑shaped to mild central beaking in middle thoracic vertebral bodies was observed in subtype 1 patients, while greater degrees of central beaking in middle thoracic vertebral bodies was observed in subtype 2 patients.

Conclusions: Spine CT findings clearly identify new radiological findings of thoracic kyphosis apex around T2 or T5 in MPS IVa patients. The degrees of central beaking at middle thoracic vertebral bodies may be a critical factor associated with different image presentations of thoracic kyphosis.

Keywords: Mucopolysaccharidosis, Spinal stenosis, Thoracic kyphosis, Thoracic vertebral body

Background

Mucopolysaccharidosis (MPS) belongs to a group of genetic disorders known as lysosomal storage diseases (LSDs). Deficiencies of specific enzymes in MPS disease interrupt the degradation of mucopolysaccharides (or glycosaminoglycans), leading to accumulation of these substances in cellular lysosomes. MPS disease includes 15 types, which are divided into 7 phenotypes according
to the specific enzyme deficiency: MPS types I, II, III, IV, VI, VII, IX [1, 2]. All phenotypes have an autosomal recessive hereditary pattern except MPS type II, which has an X-linked recessive pattern [1–3]. MPS type IVa, or Morquio A syndrome, is caused by deficiency of N-acetylgalactosamine-6-sulfate sulphatase (a catalyzed enzyme that breaks down into two glycosaminoglycans [GAG], keratan sulphate [KS] and chondroitin 6-sulphate [C6S]), and consequent gradual accumulation of KS and C6S in several organs and tissues. Because KS and C6S are the main components of proteoglycans in cartilage and bone, MPS IVa presents primarily with skeletal dysplasia and short stature [4, 5]. Skeletal deformity is defined as multiple bone dysostosis occurring as the most common initial symptom [5, 6]. Visual, auditory, cardiovascular and respiratory systems are also compromised in this multisystem disease [4, 5, 7]. Although MPS IVa is generally not believed to affect neurocognitive function [5], a recent study suggests that subtle neurocognitive involvement may exist [8]. Symptom onset typically occurs before 1 year of age in patients with rapidly progressive disease, and usually occurs in the second decade of life in patients with slowly progressive disease [6]. In individuals with phenotypes of severe disease, paralysis from cervical myelopathy, respiratory insufficiency and cardiac abnormalities may all shorten the lifespan, with death typically occurring in the second or third decade [5, 6]. In contrast, MPS IVa attenuated patients may have normal or near-normal life expectancy [5, 6].

In general, spinal involvement in MPS IVa occurs at two distinct sites. Involvement of the cervical spine, particularly spinal instability and spinal cord compression at the C1-C2 level, is a nearly universal finding and predisposes patients to myelopathy, paralysis, and sudden death [5]. Spinal cord compression due to thoracicolumbar kyphosis is uncommon but can lead to insidious paraplegia with all of its devastating consequences [9]. Prevention of these complications requires early detection and prompt treatment of cervical instability, spinal stenosis and spinal cord compression. Spinal involvement is usually progressive, but neurological deficits may occur suddenly [4]. Neurological signs and symptoms may underestimate the severity of spinal cord involvement revealed by MRI [4, 10], emphasizing the importance of advanced imaging in managing spinal disease in MPS IVa.

Recently, Solanki et al. [11] reviewed the complex anatomy and pathology of the cervical atlantoaxial region, outlining spinal involvement in MPS IVa. Through systematic evaluation and management of spinal instability, cervical and thoracolumbar spinal stenosis and spinal cord compression, irreversible neurological damage can be avoided or prevented to improve patient outcomes [11]. The correlation between clinical and neurological findings and imaging studies is particularly important [11]. CT and plain radiography are useful imaging modalities for detecting vertebral bony abnormalities. Detailed visualization of multiple spinal defects makes MRI the most appropriate and useful imaging technique for assessing the degree of spinal stenosis and spinal cord compression [11, 12]. However, few studies have assessed thoracic spinal involvements in patients with MPS IVa. Therefore, this study aimed to assess the unique thoracic spinal computed tomography and MRI image manifestations in patients with MPS IVa.

**Methods**

**Study design and sample**

This retrospective study enrolled patients with MPS IVa who were diagnosed and/or treated at MacKay Memorial Hospital from January 2010 to December 2020. 26 cases of MPS IVa were collected during this study period, including 14 outpatients and 12 inpatients. Retrospective chart review of data from above patients was performed. The inclusion criteria were having qualified spinal CT or MRI and confirmation of a known diagnosis of MPS IVa by liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for three urinary glycosaminoglycans (GAGs; dermatan sulfate [DS], heparan sulfate [HS], and keratan sulfate [KS]). Patients who did not undergo associated spinal CT or MRI radiological examination, as well as those with only postoperative images in their electronic medical records at our institute, were excluded. Finally, 12 MPS IVa patients were enrolled in this study.

**Ethical considerations**

The study protocol was approved by the medical ethics committee of MacKay Memorial Hospital (21MMHIS335e). Due to the retrospective nature of this study, the ethics committee waived signed informed consent from included patients.

**MRI and CT assessment**

All included patients received CT and/or MRI, as well as plain radiography to evaluate MPS IVa-related symptoms. CT was performed for these patients because of clinical symptoms such as respiratory insufficiency, cardiac or spinal problems using Somatom Definition Flash (Siemens Healthcare, Forchheim, Germany) or Somatom Definition AS (Siemens Healthcare, Forchheim, Germany) scanners. Subsequent reconstructed spinal CT images were obtained for image analysis using the bone window setting in the sagittal plane with 2 mm slice thickness. Spinal MRI was performed for clinical screening to assess the conditions around cervicomedullary and the thoracolumbar junction using a 1.5 T GE Signa Twinspee and Signa HDxt scanners.
study, as well as status of enzyme replacement therapy (ERT) are listed in Table 1.

Spine CT and plain radiographs
In spine CT and plain radiographs, thoracic spinal abnormalities were grouped into two subtypes: subtype 1 (defined as thoracic kyphosis apex around T2, n = 8 or 66.67%) and subtype 2 (defined as thoracic kyphosis apex around T5, n = 4 or 33.33%) (Fig. 1; Table 1). However, one patient had a thoracic kyphosis apex around T1 to T2, while another patient’s kyphosis apex occurred at around T4 to T5 in subtypes 1 and 2, respectively. Square-shaped to mild central beaking in middle thoracic vertebral bodies was observed in subtype 1, whereas greater degrees of mild to moderate central beaking in middle thoracic vertebral bodies was observed in subtype 2 (Fig. 1; Table 1). In addition, we also delineated thoracolumbar kyphosis apex around T11 to L2, and the presence of craniocervical junction abnormalities as well as odontoid dysplasia in all twelve patients (Fig. 1). Lastly, the Cobb angle of thoracic kyphosis was measured, where subtype 2 cases seemed to have a greater Cobb angle of thoracic kyphosis compared to those in subtype 1 in our study (Table 1).

Spine MRI findings
Spine MRI findings of the above eight MPS IVa patients showed relative narrowing of the spinal canal around the bony levels of T2 and T5 in subtypes 1 and 2, respectively (Fig. 2). Six patients with spinal stenosis at cervicomedullary junction was noted, three of which exhibited compressive myelopathy and received subsequent surgical decompression. However, no significant spinal cord compressive myelopathy was identified at thoracic and junction around thoracolumbar levels at the time of examination. Therefore, no surgical decompression at these levels was performed.

Discussion
The present study may be the first to provide imaging evidence from CT and MRI of subtypes of thoracic spine morphology in MPS IVa patients. MPS-related spinal dysplasia develops in most MPS IVa patients but with varying severity. Results of the present study demonstrate abnormalities of thoracic spine dysplasia in patients with MPS IVa, including subtype 1 (defined as the thoracic kyphosis around T2) and subtype 2 (defined as the thoracic kyphosis around T5). In particular, consistency is noted between CT and MRI measurements in these patients. Overall, the combined radiological approach using CT and MRI still appears to be the best approach for screening full-spinal abnormalities in MPS IVa patients, and this pilot study has again demonstrated
Table 1  Demographic characteristics and thoracic spinal radiological findings of mucopolysaccharidosis type IVa patients

| Patient | Age (y/o) at study enrollment | Gender | Clinical indications for CT/MRI exam | CT | MRI | ERT | Subtype of thoracic kyphosis | Cobb angle of thoracic kyphosis apex | Central beaking of middle thoracic vertebral body | Thoracolumbar kyphosis apex |
|---------|-------------------------------|--------|-------------------------------------|----|-----|-----|-----------------------------|---------------------------------|-------------------------------------|-----------------------------|
| 1       | 15                            | Female | Obstructive airways                 | ✓  | ✓   | ✓   | 1                            | 0–10 degrees                     | +                                   | L1                           |
| 2       | 14                            | Female | Obstructive airways and cranioce | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | +                                   | T11                          |
| 3       | 9                             | Male   | Obstructive airways, heart disease and cranioce | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | ++                                  | T12                          |
| 4       | 2                             | Female | Craniocele abnormalities            | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | ++                                  | T12                          |
| 5       | 6                             | Female | Obstructive airways                | ✓  | ✓   | ✓   | 1                            | 20–30 degrees                    | ++                                  | L2                           |
| 6       | 7                             | Female | Craniocele abnormalities           | ✓  | ✓   | ✓   | 1                            | 30–40 degrees                    | ++                                  | T11                          |
| 7       | 5                             | Male   | Obstructive airways, heart disease and cranioce | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | −                                   | L1                           |
| 8       | 15                            | Female | Obstructive airways and cranioce | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | −                                   | L1                           |
| 9       | 26                            | Male   | Obstructive airways and heart disease | ✓  | ✓   | ✓   | 1                            | 20–30 degrees                    | −                                   | T12                          |
| 10      | 1                             | Male   | Craniocele abnormalities           | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | ++                                  | L2                           |
| 11      | 1                             | Male   | Thoracic kyphosis                 | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | +                                   | T11                          |
| 12      | 28                            | Male   | Obstructive airways, heart disease and cranioce | ✓  | ✓   | ✓   | 1                            | 10–20 degrees                    | +                                   | L1                           |

CT: Computed tomography; MRI: Magnetic resonance imaging; ERT: Enzyme replacement therapy; T: Thoracic; L: Lumbar. ✓/✓/✓ indicates square-shaped vertebral body (no significant central beaking); −/−/− indicates square-shaped to mild central beaking (central beaking < 1/3 height of vertebral body); +/+/+ indicates mild to moderate central beaking (central beaking between 1/3 and 2/3 height of vertebral body).
the importance of combined radiological monitoring for managing the clinical therapy of MPS IVa patients.

Typical spinal manifestations of MPS are atlantoaxial instability (with odontoid dysplasia), thoracolumbar kyphosis/scoliosis (gibbus deformity) and cervical/lumbar developmental spinal stenosis [12]. Spine disease and its severity depend on the type of MPS and may be associated with disease activity. Atlantoaxial instability has frequently been observed in MPS IV, followed by MPS VI and MPS I; thoracolumbar kyphosis is a well-known hallmark of MPS I, but is also common in MPS II, IV, and VI, and cervical stenosis is widespread in all types of MPS except MPS III [16, 17]. Similarly, the CT findings of the present study showed that craniovertebral junction abnormalities and odontoid dysplasia were identified in all patients with MPS IVa. In addition, MPS IVa patients have common scoliosis and kyphosis of the thoracolumbar spine at T11 to L2 [18, 19], which was also observed in the present study. We further demonstrated that MPS IVa patients could be grouped into two subtypes, thoracic kyphosis apex around T2 (subtype 1) and thoracic kyphosis apex around T5 (subtype 2), although we also observed one patient in each subgroup with the thoracic kyphosis apex around T1/T2 and T4/T5 junction, which may be similar to results with a reported range of T11 to L2 instead of a precise bony level of the thoracolumbar apex. Meanwhile, the severity of central beaking in middle thoracic vertebral bodies and the Cobb angle of thoracic kyphosis were more significant in subtype 2 patients than in subtype 1 patients. Previous study has described a defect of vertebral body development causing thoracolumbar kyphosis [20]. Congenital cervical instability and kyphosis are the result of vertebral hypoplasia and are associated with a functional disconnection of the posterior spine associated with pedicle hypoplasia [21]. According to these findings, we speculated that the severity of central beaking in middle thoracic vertebral bodies might be a critical factor associated with thoracic kyphosis exhibiting an apex around different levels of T2 and T5 in MPS IVa patients. Certainly, it merits further investigation.

No guidelines are available currently for systematically assessing the extent of spinal involvement in patients with MPS IVa, as well as for identifying candidates for surgery or assessing the impact of treatment. Surgical decision making will be supported by the development of standardized risk stratification systems based on objective and measurable clinical, neurological, and radiological parameters. Although assessing dysplasia of the odontoid is more accurate in sagittal CT images than in MRI or plain radiographs due to easy identification of the lack of ossification, MRI clearly assesses a compressed spinal cord and is thus considered the gold standard for...
diagnosing spinal cord compression [22]. However, the incidence of spinal cord compression may be underestimated because MRI is usually performed in a neutral position. If the MRI option is available, it can also be used to assess the extent of compression [23]. Spinal cord compression occurs most commonly in two locations: the cervicomедullary junction and the thoracolumbar junction in children with thoracolumbar kyphosis [11]. Similarly, the spine MRI findings of the present study also indicated that compressed spinal cord around C1 to C2 could be clearly observed in the two subtypes of MPS IVa. Although we did not find severely compressed spinal cord around bony levels of T2, T5, and T11 to L2 in the two subtypes at the time of examination, results of previous studies indicated that evolution of vertebral abnormalities occurs over time in MPS patients [24, 25]. In a previous study, the kyphosis was progressive in MPS patients for whom serial radiographs were available [25], resulting in spinal problems requiring spinal decompression or fusion surgery [18]. Thus, long-term monitoring by MRI for spinal cord compression around T2 and T5 may be required in MPS IVa patients in addition to known common sites at the cervicomедullary and thoracolumbar junction. A scoring system based on MRI findings has been proposed for evaluating cervical spinal cord involvement in MPS patients [26], and a scoring system has been developed for determining the optimal timing of surgery for MPS IVa patients [27]. However, objective outcome measures and large well-designed studies are still needed to determine the efficacy of surgical and medical treatment for this patient population. Consequently, further investigation may be conducted to develop a modified scoring system for determining the optimal timing of surgery for the different subtypes of MPS IVa patients.

In a previous study where MPS-specific questionnaire was handed to patients, 68% of patients indicated that they had bone pain, and the most often reported joint pains were back pain (25.9%) and hip pain (27.8%) [28]. The pathophysiology of pain in patients with MPS is probably multifactorial. For example, glycosaminoglycan storage induces inflammation by activating toll-like receptor 4 and increasing levels of cytokines such as TNF-α has been shown with animal models in past literature [29, 30]. Furthermore, structural deformities of the spinal column may contribute to the onset of back pain, especially in the period of intense growth and development. Another previous study of MPS I patients reported cases with lumbar kyphosis had simultaneous low back pain [25]. In the present study, MPS IVa patients showed spinal kyphosis at bony levels of T2, T5, and T11 to L2. Further follow-up images are recommended for these patients if they have persistent or progressive back pain.

Therefore, in addition to focusing on the changes in thoracolumbar junction that cause clinically relevant symptoms, we must also pay attention to the possible location of new thoracic spine abnormalities revealed in our study which will also cause related clinical symptoms.

The present study has several limitations. First, as this was a retrospective study, the potential for biases is inevitable. The study cohort was not large, and the study was conducted in a single medical center in Taiwan, which may limit the generalization of results to other centers, geographic locations or populations. As MPS IVa is considered an extremely rare disease, the sample size was quite limited and did not allow us to reach definitive conclusions. Another study or larger scale research are still needed to support our thoracic spinal image findings and correlate them with clinical presentation in various subtypes of MPS IVa patients.

Conclusions
Spine CT findings clearly identify obvious bony abnormalities of cervical, thoracic, and lumbar spine in the subtypes of MPS IVa patients. MRI findings are consistent with CT measurements in these patients, and are important in neurological monitoring for spinal stenosis and the effects of clinical therapy. Overall, we suggest that the combined radiological approach using CT and MRI still provides the most appropriate and useful imaging techniques to screen for spinal abnormalities in various subtypes of MPS IVa patients. Our study results highlight again the unique image manifestations of thoracic kyphosis and associated spinal stenosis in MPS IVa patient population.

Abbreviations
ADL: Activities of daily living; CS. Chondroitin 6-sulphate; CT: Computed tomography; ERT: Enzyme replacement therapy; GAG: Glycosaminoglycans; GAINS: N-acetylgalactosamine-6-sulfate sulfatase; KS: Keratan sulphate; MPS: Mucopolysaccharidosis; MRI: Magnetic resonance imaging.

Acknowledgements
None.

Author contributions
Conceptualization, Y-TJ, P-ST, W-HH, S-CH, Y-PL, S-MC, and K-SH; Methodology, Y-TJ, P-ST, W-HH, S-CH, Y-PL, S-MC; and K-SH; Data Curation, Y-TJ, P-ST, W-HH, S-CH, Y-PL, S-MC, and K-SH; Formal Analysis, Y-TJ, P-ST, W-HH, S-CH, Y-PL, S-MC, and K-SH; Formal Analysis, Y-TJ, P-ST, W-HH, S-CH, Y-PL, S-MC, and K-SH; Writing – Original Draft Preparation, Y-TJ and K-SH; Writing – Review & Editing, Y-TJ, P-ST, W-HH, S-CH, Y-PL, S-MC, and K-SH; Supervision, Y-TJ, Y-PL, S-MC, and K-SH; Project Administration, P-ST, W-HH, and S-CH. All authors read and approved the final manuscript.

Funding
None.

Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
The study protocol was approved by the medical ethics committee of Mackay Memorial Hospital (21MMHIS335e).

Consent for publication
Due to the retrospective nature of this study, the ethics committee waived signed informed consent from included patients.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Radiology, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd, Taipei City 104, Taiwan. 2 Department of Radiology, Mackay Memorial Hospital, Hsinchu 300, Taiwan. 3 Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei 112, Taiwan. 4 Department of Medicine, Mackay Medical College, New Taipei City 252, Taiwan. 5 Nursing and Management, Mackay Junior College of Medicine, New Taipei City 112, Taiwan.

Received: 10 February 2022 Accepted: 17 July 2022

Published online: 29 July 2022

References
1. EF N JM, et al. The mucopolysaccharidosis. In: Scriver CRBA, editors. The molecular and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001.

2. Lehman TJ, Miller N, Norquist B, Underhill L, Keutzer J. Diagnosis of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v1-8.

3. Rasalkar DD, Chu WC, Hui J, Chu CM, Paunipagar BK, Li CK. Pictorial review of mucopolysaccharidosis with emphasis on MRI features of brain and spine. Br J Radiol. 2011;84(1001):469–77.

4. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis. 1996;19(3):357–65.

5. Tomatsu S, Montano AM, Okawa H, Smith M, Barrera L, Chinen Y, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931–45.

6. Montano AM, Tomatsu S, Gottesman GS, Smith M, Ori T. International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165–74.

7. Hendriks CJ, Al-Jawad M, Berger KI, Hawley SM, Lawrence R, Mc Ardle A, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36(2):309–22.

8. Davison JE, Kearney S, Horton J, Foster K, Peet AC, Hendriks CJ. Intellectual and neurological functioning in Morquio syndrome (MPS IVa). J Inherit Metab Dis. 2013;36(2):323–8.

9. Blaw ME, Langer LO. Spinal cord compression in Morquio-Brailsford’s disease. J Pediatr. 1969;74(4):593–600.

10. Hughes DG, Chadderton RD, Cowie RA, Wraith JE, Jenkins JP. MRI of the brain and cranio cervical junction in Morquio’s disease. Neuroradiology. 1997;39(5):381–5.

11. Solanki GA, Martin KW, Theroux MC, Lampe C, White KK, Shediac R, et al. Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management. J Inherit Metab Dis. 2013;36(2):339–55.

12. Teraí H, Nakamura H. Surgical management of spinal disorders in people with mucopolysaccharides. Int J Mol Sci. 2020;21(13):1171.

13. Sawamoto K, Alvarez Gonzalez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21(4):1517.

14. Drummond JC, Krane EJ, Tomatsu S, Theroux MC, Lee RR. Paraplegia after epidural-general anesthesia in a Morquio patient with moderate thoracic spinal stenosis. Can J Anaesth. 2015;62(11):45–9.

15. Koele MC, Lems WF, Willems HC. The clinical relevance of hyperkyphosis: a narrative review. Front Endocrinol (Lausanne). 2020;11:5.

16. Alden TD, Amantino H, Dalla Corte A, Lampe C, Harmatz PR, Vedolín L. Surgical management of neurological manifestations of mucopolysaccharidosis disorders. Mol Genet Metab. 2017;122:41–8.

17. White KK, Harmatz P. Orthopedic management of mucopolysaccharide disease. J Pediatr Rehabil Med. 2010;3(1):47–56.

18. Ebara S, Kinoshita T, Yuzawa Y, Takahashi J, Nakamura I, Hirabayashi H, et al. A case of mucopolysaccharidosis IV with lower leg paresis due to thoraco-lumbar kyphoscoliosis. J Clin Neurosci. 2003;10(5):358–61.

19. Roberts SB, Tsirikos AI. Thoracolumbar kyphoscoliosis with unilateral subluxation of the spine and postoperative lumbar spondylothesis in hunter syndrome. J Neurosurg Spine. 2016;24(3):402–6.

20. Clevy MA, Wraith JE. The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr. 1995;84(3):337–9.

21. Lachman RS. The cervical spine in the skeletal dysplasias and associated disorders. Pediatr Radiol. 1997;27(3):402–8.

22. Solanki GA, Sun PP, Martin KW, Hendriks CJ, Lampe C, Guffon N, et al. Cervical cord compression in mucopolysaccharidosis VI (MPS VII): findings from the MPS VI clinical surveillance program (CSIP). Mol Genet Metab. 2016;118(4):310–8.

23. Mackenzerz‑WG, Dhwawale AA, Demczko MM, Ditro C, Rogers KJ, Bober MB, et al. Flexion‑extension cervical spine MRI in children with skeletal dysplasia: Is it safe and effective? J Pediatr Orthop. 2013;33(1):91–8.

24. Leone A, Rigante D, Amato DZ, Casale R, Pedone L, Magarelli N, et al. Spinal involvement in mucopolysaccharidoses: a review. Childs Nerv Syst. 2015;31(2):203–12.

25. Tandon V, Williamson JB, Cowie RA, Wraith JE. Spinal problems in mucopolysaccharidosis I (Hurler syndrome). J Bone Joint Surg Br. 1996;78(6):938–44.

26. Lachman R, Martin KW, Castro S, Basto MA, Adams A, Teles EL. Radiologic and neuroradiologic findings in the mucopolysaccharidoses. J Pediatr Rehabil Med. 2010;3(2):109–18.

27. Mollmann C, Lampe CG, Muller‑Forell W, Scapa M, Harmatz P, Schwarz M, et al. Development of a scoring system to evaluate the severity of cranio‑cervical spinal cord compression in patients with mucopolysaccharidosis IV (Morquio A Syndrome). JIMD Rep. 2013;11:65–72.

28. Brands MM, Gunorg D, van den Hout J, Karstens FP, Oussoren E, Plug J, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis. 2015;38(2):323–31.

29. Simonov CM, D’Angelo M, He X, Elyahu E, Shtraizent N, Haskins ME, et al. Mechanism of glycosaminoglycan‑mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue disorders. Am J Pathol. 2008;172(1):112–22.

30. Simonov CM, Ge Y, Elyahu E, He X, Jepsen KJ, Schuchman EH. Involvement of the toll‑like receptor 4 pathway and use of TNF‑alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A. 2010;107(1):222–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress. Learn more: biomedcentral.com/submissions